David R. Buckler is a notable inventor based in Sleepy Hollow, NY, with a significant contribution to the field of biotechnology. He holds a total of four patents, showcasing his innovative approach to scientific challenges. His work primarily focuses on genetic modifications and therapeutic proteins, which have the potential to impact various medical fields.

Latest Patents

One of Buckler's latest patents is the development of a common light chain mouse. This genetically modified mouse is designed to express only one or two human light chain variable domains, which are crucial for antibody production. Another significant patent involves bispecific epitope-binding proteins that are fully human, comprising two different heavy chains that associate with an identical light chain. Additionally, he has worked on anti-FGFR1c antibody-FGF21 fusion proteins, which serve as agonists of FGF21 signaling, providing potential treatments for metabolic disorders.

Career Highlights

David R. Buckler is currently employed at Regeneron Pharmaceuticals, Inc., a leading biotechnology company known for its innovative therapies. His work at Regeneron has allowed him to collaborate with other talented scientists and contribute to groundbreaking research in the field.

Collaborations

Some of his notable coworkers include Andrew J. Murphy and John R. McWhirter, who have also made significant contributions to the field of biotechnology. Their collaborative efforts have further advanced the research and development of innovative therapies.

Conclusion

David R. Buckler's contributions to biotechnology through his patents and work at Regeneron Pharmaceuticals highlight his role as a key innovator in the field. His research continues to pave the way for advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.